CRC
Glasgow, United Kingdom
CRC
Glasgow, United Kingdom

Time filter

Source Type

News Article | May 26, 2017
Site: www.eurekalert.org

TU Dresden is going establish two new Collaborative Research Centres (CRC) and an additional CRC with TUD participation will be continued, the German Research Foundation (DFG) announced on 26 May 2017. "Collaborative Research Centres approved by the DFG are always an indicator of a university's research strength. I am therefore particularly delighted that our two new applications as well as our renewal proposal have been successful", states Prof. Hans Müller-Steinhagen, Rector of TU Dresden. The new Humanities and Social Sciences CRC 1285 is set within an interdisciplinary research alliance and deals with the phenomena of "vituperations and insults". "The approval of the CRC "Invectivity - Constellations and Dynamics of Degradation" is a particular highlight in my opinion: firstly, this issue is highly topical and sensitive - especially here in Dresden - and secondly, the CRC will further strengthen the Humanities at TU Dresden. The Humanities are an inherent and indispensable component of the broad and interdisciplinary range of subjects at TU Dresden. The approval encourages us to continue our strategy - to unite engineering, natural sciences and the humanities under one roof of a technical university and to utilise the resulting synergy potentials," elaborates Prof. Müller-Steinhagen. At the same time the CRC/Transregio 205 "The Adrenal: Central Relay in Health and Disease" will be newly set up at the University Hospital Carl Gustav Carus, which explores the adrenal as the central human stress organ. The CRC/Transregio 67 "Functional Biomaterials for Controlling Healing Processes in Bone and Skin", run jointly by the Leipzig and Dresden universities will be continued for a third funding period.


News Article | May 23, 2017
Site: www.eurekalert.org

ATS 2017, WASHINGTON, DC--A lung cancer diagnosis appears to put patients at the greatest risk of suicide when compared to the most common types of non-skin cancers, according to new research presented at the ATS 2017 International Conference. Researchers analyzed 3,640,229 patients in the Surveillance, Epidemiology, and End Results (SEER) database and looked at suicide deaths for all cancers and for lung, prostate, breast and colorectal cancers individually. Over a 40 year period, cancer diagnoses were associated with 6,661 suicides. "We wanted to see what the impact of one of life's most stressful events is on patients," said Mohamed Rahouma, MD, a post-doctoral cardiothoracic research fellow at Weill Cornell Medical College/New York Presbyterian Hospital. "I think it's fair to say that most clinicians don't think about suicide risk in cancer patients. This study, I hope, will change that by making us more aware of those at greatest risk of suicide so that this catastrophe in the care of our patients doesn't happen." Among lung cancer patients, Asians have a more than 13-fold and men a nearly 9-fold increase in suicides. Other factors that increased suicide risk were being older, being widowed, refusing surgical treatment and having a difficult-to-treat (metastatic) type of lung cancer. The authors noted that over the 40-year study period, suicide rates decreased, most notably for lung cancer when compared to the other three most common cancers. "While cancer diagnosis counselling is an established practice, especially if a patient seems depressed, referral for ongoing psychological support and counseling typically does not happen," Dr. Rahouma said. "This represents a lost opportunity to help patients with a devastating diagnosis." Lung cancer patients have the highest malignancy-associated suicide rate in USA: a population based analysis. Authors: M. Rahouma, M. Kamel, A. Nasar, S. Harrison, B. Lee, B. Stiles, N. Altorki, J.L. Port; Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY - New York, NY/US Previous studies have reported that the psychological and social distresses associated with cancer diagnosis have led to an increase in suicides compared to the general population. In the current study we sought to explore lung cancer associated suicide rates in a large national database compared to the general population as well as to the three most prevalent non-skin cancers [breast, prostate, colorectal cancer (CRC)]. The Surveillance, Epidemiology, and End Results (SEER) database (1973-2013) was retrospectively queried to identify cancer associated suicide deaths in all cancers combined, as well as, for each of lung, prostate, breast, or colorectal cancers. Suicide incidence and standardized mortality ratio (SMR) were estimated by using SEER*Stat 8.3.2 program. Suicidal rate for the general US population was obtained from National Vital Statistics Reports, Vol.64, No. 2. Furthermore, suicidal trends over time and timing from cancer diagnosis to suicide were estimated for each cancer type. Among lung cancer patients, suicide SMR of different demographic, social and tumor related factors were identified. Among 3,640,229 patients diagnosed with cancer in the study period, 6661 patients committed suicide. The cancer associated suicide rate was 27.5/100,000 person-years (SMR=1.6) compared to 13 /100,000 person-years for the general US population. The highest suicide risk was observed in lung cancer patients (SMR= 4.2) followed by CRC (SMR=1.4), breast cancer (SMR=1.4) and prostate cancer (SMR=1.2). Median time to suicide was 7 months from diagnosis in lung cancer, 56 months in prostate ca, 52 months in breast cancer and 37 months in CRC (p There was a trend towards the decrease in suicide SMR over time, which is most notable for lung cancer compared to the other three cancers (Figure). Among lung cancer patients; suicide SMR was higher in males (SMR=8.8), Asians (SMR=13.7), widowed patients (SMR=11.6), older patients (70-75 years; SMR=12), patients with undifferentiated tumors (SMR 8.6) or small cell lung carcinoma (SCLC) histology (SMR=11.2), patients presenting with metastatic disease (SMR=13.9) and in patients who refused to receive surgical treatment (SMR=13). The cancer associated suicide rate is nearly twice that of US-general population. Suicide risk is highest among lung cancer patients, particularly older patients, widowed, males, and patients with unfavorable tumor characteristics. It is important to identify these high risk patients in order to provide the proper psychological assessment, support, and counselling to reduce these rates.


BOCA RATON, Fla., April 18, 2017 (GLOBE NEWSWIRE) -- CRC Press announces the publication of Remediation Engineering: Design Concepts, Second Edition co-authored by the late Dr. Suthan S. Suthersan and colleagues, John Horst, Matthew Schnobrich, Nicklaus Welty, and Jeff McDonough. Two decades ago, contaminated groundwater supplies were addressed by containing football field-sized areas and spending years excavating, injecting molasses as a bio-agent, or pumping millions of gallons of water through a filter. It was costly, resource-consuming and slow. Now, 20 years later, spurred by the fundamental advancements that have taken place in the remediation engineering field during the last two decades, Dr. Suthersan set out to, once again, change the industry with the release of this second edition of his groundbreaking book Remediation Engineering: Design Concepts. The latest edition covers the entire spectrum of current technologies that are employed in the industry, while discussing future trends and how practitioners should anticipate and adapt to those needs. “The focus is always on completing remediation activities in a more cost-effective and timely manner. The challenge has consistently been to find new technologies to meet the changing landscape of new waves of contaminants and constantly evolving regulatory standards,” explained Dr. Suthersan. “Advanced, practical, state-of-the-science concepts are presented on remediation hydraulics, smart investigations, digital conceptual site models, reagent delivery mechanisms, remediation geochemistry and combined remedies. I believe this second edition will guide engineers, scientists, regulators, students, and researchers as we look forward to the next 20 years of remediation developments.” Prior to his passing, Dr. Suthan S. Suthersan was chief technical officer and executive vice president at Arcadis, the leading global design and consultancy firm for natural and built assets. With more than 35 years of experience and participation in hundreds of environmental remediation projects worldwide, he became known as a leading expert in the remediation engineering field. Co-authors of the book include Arcadis-employed, globally-recognized industry experts, John Horst, (PE), executive director of technical knowledge and innovation; Matthew R. Schnobrich, technical expert and associate vice president; Nicklaus Welty, (PG, CPG), director of site investigation, and Jeff McDonough, (PE), principal engineer. Further details and purchase information can be found here - http://arcad.is/redc-pr. About CRC Press: CRC Press is a premier publisher of scientific, technology and medical resources, reaching around the globe to collect essential reference material and the latest advances and making them available to researchers, academics, professionals, and students in a variety of accessible formats. CRC Press is a member of Taylor & Francis Group, an Informa business. For more information, visit www.crcpress.com. About Arcadis: Arcadis is the leading global Design & Consultancy firm for natural and built assets. Applying our deep market sector insights and collective design, consultancy, engineering, project and management services we work in partnership with our clients to deliver exceptional and sustainable outcomes throughout the lifecycle of their natural and built assets. We are 27,000 people active in over 70 countries that generate $3.5 billion in revenues. We support UN-Habitat with knowledge and expertise to improve the quality of life in rapidly growing cities around the world. Arcadis. Improving quality of life. www.arcadis.com


BOCA RATON, Fla., April 18, 2017 (GLOBE NEWSWIRE) -- CRC Press announces the publication of Remediation Engineering: Design Concepts, Second Edition co-authored by the late Dr. Suthan S. Suthersan and colleagues, John Horst, Matthew Schnobrich, Nicklaus Welty, and Jeff McDonough. Two decades ago, contaminated groundwater supplies were addressed by containing football field-sized areas and spending years excavating, injecting molasses as a bio-agent, or pumping millions of gallons of water through a filter. It was costly, resource-consuming and slow. Now, 20 years later, spurred by the fundamental advancements that have taken place in the remediation engineering field during the last two decades, Dr. Suthersan set out to, once again, change the industry with the release of this second edition of his groundbreaking book Remediation Engineering: Design Concepts. The latest edition covers the entire spectrum of current technologies that are employed in the industry, while discussing future trends and how practitioners should anticipate and adapt to those needs. “The focus is always on completing remediation activities in a more cost-effective and timely manner. The challenge has consistently been to find new technologies to meet the changing landscape of new waves of contaminants and constantly evolving regulatory standards,” explained Dr. Suthersan. “Advanced, practical, state-of-the-science concepts are presented on remediation hydraulics, smart investigations, digital conceptual site models, reagent delivery mechanisms, remediation geochemistry and combined remedies. I believe this second edition will guide engineers, scientists, regulators, students, and researchers as we look forward to the next 20 years of remediation developments.” Prior to his passing, Dr. Suthan S. Suthersan was chief technical officer and executive vice president at Arcadis, the leading global design and consultancy firm for natural and built assets. With more than 35 years of experience and participation in hundreds of environmental remediation projects worldwide, he became known as a leading expert in the remediation engineering field. Co-authors of the book include Arcadis-employed, globally-recognized industry experts, John Horst, (PE), executive director of technical knowledge and innovation; Matthew R. Schnobrich, technical expert and associate vice president; Nicklaus Welty, (PG, CPG), director of site investigation, and Jeff McDonough, (PE), principal engineer. Further details and purchase information can be found here - http://arcad.is/redc-pr. About CRC Press: CRC Press is a premier publisher of scientific, technology and medical resources, reaching around the globe to collect essential reference material and the latest advances and making them available to researchers, academics, professionals, and students in a variety of accessible formats. CRC Press is a member of Taylor & Francis Group, an Informa business. For more information, visit www.crcpress.com. About Arcadis: Arcadis is the leading global Design & Consultancy firm for natural and built assets. Applying our deep market sector insights and collective design, consultancy, engineering, project and management services we work in partnership with our clients to deliver exceptional and sustainable outcomes throughout the lifecycle of their natural and built assets. We are 27,000 people active in over 70 countries that generate $3.5 billion in revenues. We support UN-Habitat with knowledge and expertise to improve the quality of life in rapidly growing cities around the world. Arcadis. Improving quality of life. www.arcadis.com


News Article | April 25, 2017
Site: marketersmedia.com

Global Caps & Closures Packaging market is estimated at $47.3 billion in 2014 and is expected to reach $68.9 billion by 2022 growing at a CAGR of 4.8% during the forecast period 2014 to 2022Pune , India - April 25, 2017 /MarketersMedia/ — Caps & Closures Industry Description The Global Caps & Closures Packaging market is estimated at $47.3 billion in 2014 and is expected to reach $68.9 billion by 2022 growing at a CAGR of 4.8% during the forecast period 2014 to 2022. Fear about product safety & security, increasing per capita consumption in rising economies and modern caps for shelf visibility are the factors driving the market growth. Sluggish demand for caps & closures is hindering the market while the product improvement provides an opportunity for the market growth. Rise in demand for metal cans acts as a driving factor in the growth of metal caps and closures market. Plastic screws govern the closure type in beverages since they are broadly used in dressings, condiments, and soft & alcoholic drinks. Asia Pacific held the major market for the caps and closures market in terms of both revenue and volume and is projected to stay as the market leader over the forecast period. Latin America is anticipated to be one of the fastest growing regions among the global market. Request for Sample Report @ https://www.wiseguyreports.com/sample-request/231326-caps-closures-market-outlook-global-trends-forecast-and-opportunity-assessment-2014-2022 The key players in the market include, Bericap, Tetra Laval International SA, Crown Holdings inc., Closure Systems International (CSI), Dätwyler Holding Incorporated, Amcor Ltd., Silgan Holdings Inc., RPC Group, Reynolds Group Holdings Limited and Rexam Plc. Types Covered: • Screw Caps • Over Caps • Liquid Carton Closures • Can Ends • Lug Closure • Lids • Dispensing Closures o Disc-Top Closures o Trigger Closures o Flip Top Closures o Dropper Closures • Crowns • Pumps & Sprays • Rubber Stoppers • Tamper Evident Closures • Cork • Aerosol Sprays • Peel-Off Foils • Child-Resistant Closures (CRC) • Glass Stoppers Materials Covered: • Plastic Closures • Metal Closures o Polypropylene (PP) o Polyethylene (PE) • Rubber & Cork • Other Materials o Glass o Paper Board o Rubber o Wood Closures o Elastomers Leave a Query @ https://www.wiseguyreports.com/enquiry/231326-caps-closures-market-outlook-global-trends-forecast-and-opportunity-assessment-2014-2022 Applications Covered: • Pharma o Tubes o Parenteral Containers o Bottles • Beverage o Bottles o Pouches o Beer o Other Beverages • Industrial o Steel Drums o Barrels o Plastic Containers o Cans o Plastic Drums • Food o Pouches o Cartons o Jars o Cans • Personal Care & Home Care o Aerosols o Bottles o Tubes o Pouches • Others Regions Covered: • North America o US o Canada • Europe o Germany o France o Italy o UK o Spain • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia • Rest of the World o Latin America o Middle East o Africa o Others What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 8 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=231326 Continued... Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK) Contact Info:Name: NORAH TRENTEmail: sales@wiseguyreports.comOrganization: WISE GUY RESEARCH CONSULTANTS PVT LTDAddress: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028Phone: +91 841 198 5042Source URL: http://marketersmedia.com/caps-closures-market-2017-global-analysis-opportunities-and-forecast-to-2022/190076For more information, please visit https://www.wiseguyreports.com/sample-request/231326-caps-closures-market-outlook-global-trends-forecast-and-opportunity-assessment-2014-2022Source: MarketersMediaRelease ID: 190076


News Article | April 29, 2017
Site: www.prlog.org

Owner and Founder of Dictionary Jumpstart, Anissa Nierenberger, publishes her third book. -- Anissa R. Nierenberger, RPR, CRR, CRC, CRI, owner and founder of Dictionary Jumpstart ™ (DJ), a dictionary building software company for court reporters and broadcast captioners, has released a brand new book titled,Tailored specifically to help realtime captioners and reporters,was written to help improve the dictionaries of professionals in the industry. As a 25-year veteran realtime captioner and instructor, this is Nierenberger's third book withbeing the second in a series. Her first book,, has sold over 5,000 copies.will eliminate any word boundary issues when using words that begin or end with: after, all, down, ever, off, on, out, over, up and under," shares Nierenberger. "If you know you want to become a better realtimer but aren't sure where to start,is a simple, small book that will easily get you on your way to better realtime." This book encapsulates a portion of how Nierenberger trains reporters to become better realtime reporters or transition into CART or broadcast captioning.andare both available for purchase at LearnToCaption.com.Founded in 2000, Dictionary Jumpstart is a cutting-edge, Realtime Dictionary Software. For court reporters, broadcast captioners and anyone in the steno industry, the software can help build, clean and enhance any reporter's dictionary. Dictionary Jumpstart is compatible with any CAT software and breaks down vocabulary into ten versions including: Environment, Food & Health, Media, Names, Phrases, Sports, Vocabulary, Idioms, History and World. Five modules have been approved to earn PDCs by NCRA. The software can be purchased at the company's website www.LearnToCaption.com . In addition to the Dictionary Jumpstart software and books available, LearnToCaption.com is also a valuable tool for reporters looking for training opportunities as well as general resources and information about the industry.Visit www.LearnToCaption.com for more information and to purchase Dictionary Jumpstart or training courses.


Collaboration will allow OCB's suite of precision oncology In Vitro Diagnostic tests to be rolled out across the People's Republic of China OXFORD, England, April 18, 2017 /PRNewswire/ -- Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced a strategic collaboration with  My-BioMed Biotechnology Ltd. based in Ningbo, Zhejiang, China. Oxford Cancer Biomarkers announces strategic collaboration with My-BioMed Biotechnology Ltd. The partnership includes a licencing deal that will allow My-BioMed Biotechnology Ltd. to access OCB's ColoTox, ColoProg and ColoPredict technologies and to drive uptake across the PRC via a purpose built biomedical laboratory in Ningbo Meishan FTZ. OCB has developed a suite of diagnostic tests for colorectal cancer (CRC) to personalise current treatment pathways and plans to develop similar tests for other cancer indications. As of 2015, 274,000 new cases of colorectal cancer are diagnosed every year in the People's Republic of China, 190,400 of these cases prove fatal. My-BioMed (MBM) is a leading precision medicine organisation which focused on bringing global innovation to the Chinese market. The team at MBM has extensive experience in product development and launch including clinical development, regulatory strategy, clinical laboratory services, sales and marketing. MBM's core business model is driven by patient and clinician needs. Jackson Zhu, CEO of MBM, commented "We are very happy to launch the first three proprietary CRC diagnostic tests discovered at Oxford University and developed by OCB, aimed at specifically benefitting patients in China. Both MBM and OCB have solidified through this partnership, a long-term commitment to China, with the aim of developing and launching a suite of unique diagnostic products." Prof David Kerr, Chief Medical Officer of OCB, commented "Our strategic partnership with MBM will allow patients across China to access OCB's suite of precision oncology diagnostic technologies. We are looking forward to working closely with MBM to tailor our offerings to the specific needs of the Chinese market and building a robust product pipeline of diagnostics specifically aimed at the Chinese population. This is an important step in our mission to drive global access to technologies that allow patient stratification and individually tailored treatment pathways." About Oxford Cancer Biomarkers Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient.  Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division in Oxford University. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University. Investors in OCB include Longwall Venture Partners LLP, Esperante BV and the University. For more information, please visit: http://www.oxfordcancerbiomarkers.com Contact detailsOxford Cancer Biomarkers Ltd           Tel:  +44 1865 784743Prof.Nick La Thangue, CEO / David Oxlade, Chairman About Ningbo My-BioMed Biotechnology Co.,Ltd.  In pursuit of its vision of "Bridging World Innovation in Precision Medicine", My-BioMed (MBM) is dedicated to providing personalized solutions to clinicians and patients, and to building an integrated commercialization platform for innovation. Supported by Ningbo Meishan's Healthcare industry development strategy, MBM, established in May 2016, has attracted a group of talented individuals with experience across a range of disciplines including business development, market access, clinical development, registration, clinical lab services, sales and marketing. Located at Ningbo Meishan Free Trade Port, My-BioMed Clinical Laboratory, MBM wholly owned subsidiary, has been granted pre-approval from the Health and Family Plan Commission, and will be certified within this year. Ningbo My-BioMed Biotechnology Co.,Ltd.    E-Mail:info@my-biomed.com  CEO:  Jackson Zhu Photo - http://photos.prnasia.com/prnh/20170414/1826123-1


LONDON--(BUSINESS WIRE)--Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the China Food and Drug Administration (“CFDA”) has acknowledged acceptance of the New Drug Application (“NDA”) for fruquintinib for the treatment of patients with advanced colorectal cancer, which triggers a milestone payment of RMB30.8 million (US$4.5 million) from Lilly to Chi-Med. The NDA is supported by data from the successful FRESCO study, a Phase III pivotal registration trial of fruquintinib in 416 patients with locally advanced or metastatic colorectal cancer (“CRC”) in China, which was highlighted in an oral presentation at the American Society of Clinical Oncology Annual Meeting on June 5, 2017. CRC is the second most common cancer type in China, with about 380,000 new cases per year, according to National Central Cancer Registry of China. There were approximately 1.5 million new CRC cases globally in 2015 which are expected to increase to approximately 1.7 million new cases per year by 2020, according to Frost & Sullivan. Fruquintinib is a highly selective small molecule drug candidate that has been shown to inhibit vascular endothelial growth factor receptor (“VEGFR”) 24 hours a day via an oral dose, with lower off-target toxicities compared to other targeted therapies. Its tolerability, along with its clean drug-drug interaction profile demonstrated to date, may enable rational combination with other cancer therapies such as in our ongoing clinical trials of fruquintinib in combination with chemotherapy and targeted therapy. At an advanced stage, tumors secrete large amounts of VEGF, a protein ligand, to stimulate formation of excessive vasculature (angiogenesis) around the tumor to provide greater blood flow, oxygen, and nutrients to the tumor. VEGF and VEGFR play pivotal roles in tumor-related angiogenesis, and fruquintinib inhibits the VEGF/VEGFR pathway. This represents an important therapeutic strategy in blocking the development of new blood vessels essential for tumors to grow and invade. Fruquintinib is currently under joint development in China by Chi-Med and its partner Lilly. Chi-Med and Lilly jointly announced top-line results from the FRESCO CRC trial on March 3, 2017. In addition, fruquintinib is being studied in China in a Phase III pivotal trial in non-small cell lung cancer (“NSCLC”), known as FALUCA; and a Phase II study using fruquintinib combined with Iressa® (gefitinib) in the first-line setting for patients with advanced or metastatic NSCLC. Other studies currently being planned, and soon to be initiated, include a Phase III study in gastric cancer in combination with paclitaxel in China, new studies in the United States, and certain exploratory studies in combination with other oncology agents. Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com. This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect Chi-Med’s current expectations regarding future events, including its expectations for the clinical development of fruquintinib, plans to initiate clinical studies for fruquintinib, its expectations as to whether such studies would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates, timing and availability of subjects meeting a study’s inclusion and exclusion criteria, changes to clinical protocols or regulatory requirements, unexpected adverse events or safety issues, the ability of drug candidate fruquintinib to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions, to gain commercial acceptance after obtaining regulatory approval, the potential market of fruquintinib for a targeted indication and the sufficiency of funding. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med’s filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise. This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.


Anderson G.,CRC | Maes M.,Chulalongkorn University
Current Pharmaceutical Design | Year: 2014

This paper reviews recent work on the biological underpinnings of clinical depression emphasizing the crucial role of immunoinflammatory and oxidative and nitrosative stress (O&NS) pathways in driving changes in neuronal regulating tryptophan catabolites (TRYCATs). The essence of the association of O&NS pathways with autoimmune responses in depression is via damage to lipid membranes, anchorage molecules and functional proteins that lead to changes in their chemical structures creating new modified epitopes (neoepitopes), which are highly immunogenic. The abovementioned pathways together with decreased antioxidant levels, including zinc, coenzyme Q10, glutathione and vitamin E, and melatonin are intimately involved in different aspects of depression, including mitochondrial functions and the regulation of cAMP/circadian genes, allowing for impacts across different aspects of symptom patterning. Immuno-inflammatory and O&NS processes may additionally cause alterations in blood-brain barrier permeability and neuroprogression, that is tissue damage, including neurodegeneration and apoptosis, and decreased neurogenesis and neuroplasticity. Activation of those interconnected pathways is relevant to the pathophysiology of acute and chronic depression and the progressive course (staging) of clinical depression. This implies that compounds that target these pathways may be useful to treat acute episodes and prevent further progression of the disease. We herein review some promising compounds, such as melatonin, melatonin receptor agonists, allopregnanolone, PDE4 inhibitors, statins, aspirin, sodium benzoate, tryptophan-enriched diets, and antioxidants, including epigallocatechin gallate, curcumin, quercitin, alpha-lipoic acid and resveratrol. © 2014 Bentham Science Publishers.


The biological underpinnings to the etiology and course of neurodegeneration in Parkinson's disease are an area of extensive research that has yet to produce an early biological marker or disease-slowing or preventative treatment. Recent conceptualizations of Parkinson's disease have integrated immuno-inflammation and oxidative and nitrosative stress occurring in depression, somatization and peripheral inflammation into the course of Parkinson's disease. We review the data showing the importance of immuno-inflammatory processes and oxidative and nitrosative stress in such classically conceived 'comorbidities', suggesting that lifetime, prodromal and concurrent depression and somatization may be intricately involved in the etiology and course of Parkinson's disease, rather than psychiatric comorbidities. This produces a longer term developmental perspective of Parkinson's disease, which incorporates tryptophan catabolites (TRYCATs), lipid peroxidation, sirtuins, cyclic adenosine monophosphate, aryl hydrocarbon receptor, and circadian genes. This integrates wider bodies of data pertaining to neuronal loss in Parkinson's disease, emphasizing how these interact with susceptibility genes to drive changes in mitochondria, blood-brain barrier permeability and intercellular signalling. We review this data here in the context of neurodegeneration in Parkinson's disease and to the future directions indicated for slowing disease progression. © 2013 Springer Science+Business Media.

Loading CRC collaborators
Loading CRC collaborators